Two-year results from the recently-completed HARBOR trial showed that some patients with wet AMD fare as well from Lucentis (ranibizumab) injections on an as-needed basis compared to a monthly basis. The original Lucentis trial recommended monthly dosing until the eye stabilized. The follow-up study, however, found that 93% of patients responded well with an average [Read More]
Category: Therapies, Treatments, and Procedures
Medicare Approves Payment for Argus® II Retinal Prosthesis System
Payments Will Facilitate Beneficiary Access to Argus II in both Inpatient and Outpatient Settings Sylmar, CA- August 15, 2013—Second Sight Medical Products, Inc. today announced that The Argus® II Retinal Prosthesis System (Argus II) has been approved by the Centers for Medicare and Medicaid Services (CMS) beginning October 1, 2013. These payments are designed to support [Read More]
Gene Therapy Without Retinal Risk
Researchers have developed a method of delivering genes to the inner layers of the retina without the risks associated with injection into the delicate tissues themselves. This less invasive technique has been carried out successfully in animal models by a research team led by Drs. John G. Flannery and David V. Schaffer at the University [Read More]
What Should I Ask My Doctor?
by Dan Roberts Updated September 2018 One of the most common problems encountered by people who are first diagnosed with macular degeneration is what to ask the doctor. The news usually takes us by surprise, and we may have never even heard of the disease before. To compound our confusion, many doctors do not have [Read More]
Preferential Hyperacuity Perimetry (PHP)
A Method of Early Detection of AMD Progression by Dan Roberts Carl Zeiss Meditec, Inc. has developed a device that is proving to be an effective tool for early detection of age-related macular degeneration (AMD). Called the PreView PHP™ (Preferential Hyperacuity Perimetry), it identifies deviations in the retina using a vision test based upon the [Read More]